drugset / Trial / NCT05657184
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
Phase 1
Completed
12 enrolled
Regend Therapeutics
Peking Union Medical College Hospital · collabRegend Therapeutics XLotus (Jiangxi) Co, Ltd. · collabRuijin Hospital · collabThe First Affiliated Hospital of Guangzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 in treatment of IPF. Different doses of REGEND001 is evaluated to establish a dose-response relationship and to suggest appropriate dose for subsequent clinical trials.
Timeline
- Start
- 2021-07-19
- Primary completion
- 2023-06-09
- Completion
- 2023-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REGEND001 | Cell therapy | — | — |